Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL I V RTU IN PLASTIC CONTAINER versus SOLOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL I V RTU IN PLASTIC CONTAINER versus SOLOSEC.
FLAGYL I.V. RTU IN PLASTIC CONTAINER vs SOLOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
Secnidazole is a nitroimidazole antibiotic that exerts its bactericidal activity by entering the bacterial cell and inhibiting DNA synthesis. The nitro group of secnidazole is reduced intracellularly to form free radicals and other reactive intermediates that damage bacterial DNA.
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
2 g orally as a single dose for trichomoniasis.
None Documented
None Documented
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
Terminal elimination half-life approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Renal: approximately 75% as unchanged drug; fecal/biliary: minor (estimated <10%)
Category C
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic